1. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.
Stroke 1993;24:35-41.
2. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges.
Lancet Neurol 2010;9:689-701.
3. Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage.
N Engl J Med 2001;344:1450-1460.
4. Gurol ME, Greenberg SM. Management of intracerebral hemorrhage.
Curr Atheroscler Rep 2008;10:324-331.
5. Song TJ, Kim J, Song D, Yoo J, Lee HS, Kim YJ, et al. Total cerebral small-vessel disease score is associated with mortality during follow-up after acute ischemic stroke.
J Clin Neurol 2017;13:187-195.
6. Gurol ME. Molecular neuroimaging in vascular cognitive impairment.
Stroke 2016;47:1146-1152.
7. de Laat KF, van Norden AG, Gons RA, van Oudheusden LJ, van Uden IW, Bloem BR, et al. Gait in elderly with cerebral small vessel disease.
Stroke 2010;41:1652-1658.
9. Wolma J, Nederkoorn PJ, Goossens A, Vergouwen MD, van Schaik IN, Vermeulen M. Ethnicity a risk factor? The relation between ethnicity and large- and small-vessel disease in White people, Black people, and Asians within a hospitalbased population.
Eur J Neurol 2009;16:522-527.
10. Mok V, Kim JS. Prevention and management of cerebral small vessel disease.
J Stroke 2015;17:111-122.
13. Jin C, Li G, Rexrode KM, Gurol ME, Yuan X, Hui Y, et al. Prospective study of fasting blood glucose and intracerebral hemorrhagic risk.
Stroke 2018;49:27-33.
14. Lauer A, Greenberg SM, Gurol ME. Statins in intracerebral hemorrhage.
Curr Atheroscler Rep 2015;17:46.
15. Breteler MM, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den Hout JH, et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study.
Neurology 1994;44:1246-1252.
16. Charidimou A, Boulouis G, Pasi M, Auriel E, van Etten ES, Haley K, et al. MRI-visible perivascular spaces in cerebral amyloid angiopathy and hypertensive arteriopathy.
Neurology 2017;88:1157-1164.
17. Pasi M, Charidimou A, Boulouis G, Auriel E, Ayres A, Schwab KM, et al. Mixed-location cerebral hemorrhage/microbleeds: underlying microangiopathy and recurrence risk.
Neurology 2018;90:e119-e126.
18. Smith EE, Romero JR. Mixed emotions: what to do with patients who have lobar and deep hemorrhages on MRI?
Neurology 2018;90:55-56.
19. Gurol ME, Greenberg SM. Cerebral amyloid angiopathies. In : Caplan LR, Biller J, editors. Uncommon Causes of Stroke 3rd ed. Cambridge, UK: Cambridge University Press; 2018. p. 534-544.
20. Charidimou A, Boulouis G, Roongpiboonsopit D, Auriel E, Pasi M, Haley K, et al. Cortical superficial siderosis multifocality in cerebral amyloid angiopathy: a prospective study.
Neurology 2017;89:2128-2135.
21. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria.
Neurology 2001;56:537-539.
22. Linn J, Halpin A, Demaerel P, Ruhland J, Giese AD, Dichgans M, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy.
Neurology 2010;74:1346-1350.
23. Reijmer YD, van Veluw SJ, Greenberg SM. Ischemic brain injury in cerebral amyloid angiopathy.
J Cereb Blood Flow Metab 2016;36:40-54.
24. Pasi M, Boulouis G, Fotiadis P, Auriel E, Charidimou A, Haley K, et al. Distribution of lacunes in cerebral amyloid angiopathy and hypertensive small vessel disease.
Neurology 2017;88:2162-2168.
25. Smith EE, Lee JM. Lacunes: black holes in our understanding of cerebral amyloid angiopathy.
Neurology 2017;88:2158-2159.
26. Verdura E, Hervé D, Scharrer E, Amador Mdel M, Guyant-Maréchal L, Philippi A, et al. Heterozygous HTRA1 mutations are associated with autosomal dominant cerebral small vessel disease.
Brain 2015;138(Pt 8):2347-2358.
28. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia.
Nature 1996;383:707-710.
29. Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. Cadasil.
Lancet Neurol 2009;8:643-653.
30. Gunda B, Hervé D, Godin O, Bruno M, Reyes S, Alili N, et al. Effects of gender on the phenotype of CADASIL.
Stroke 2012;43:137-141.
31. Chabriat H, Hervé D, Duering M, Godin O, Jouvent E, Opherk C, et al. Predictors of clinical worsening in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: prospective cohort study.
Stroke 2016;47:4-11.
32. Nozaki H, Sekine Y, Fukutake T, Nishimoto Y, Shimoe Y, Shirata A, et al. Characteristic features and progression of abnormalities on MRI for CARASIL.
Neurology 2015;85:459-463.
33. Mendioroz M, Fernández-Cadenas I, Del Río-Espinola A, Rovira A, Solé E, Fernández-Figueras MT, et al. A missense HTRA1 mutation expands CARASIL syndrome to the Caucasian population.
Neurology 2010;75:2033-2035.
34. Nishimoto Y, Shibata M, Nihonmatsu M, Nozaki H, Shiga A, Shirata A, et al. A novel mutation in the HTRA1 gene causes CARASIL without alopecia.
Neurology 2011;76:1353-1355.
35. Plaisier E, Gribouval O, Alamowitch S, Mougenot B, Prost C, Verpont MC, et al. COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps.
N Engl J Med 2007;357:2687-2695.
36. Verdura E, Hervé D, Bergametti F, Jacquet C, Morvan T, Prieto-Morin C, et al. Disruption of a miR-29 binding site leading to COL4A1 upregulation causes pontine autosomal dominant microangiopathy with leukoencephalopathy.
Ann Neurol 2016;80:741-753.
37. Bugiani M, Kevelam SH, Bakels HS, Waisfisz Q, Ceuterick-de Groote C, Niessen HW, et al. Cathepsin A-related arteriopathy with strokes and leukoencephalopathy (CARASAL).
Neurology 2016;87:1777-1786.
38. Sellal F, Wallon D, Martinez-Almoyna L, Marelli C, Dhar A, Oesterlé H, et al. APP mutations in cerebral amyloid angiopathy with or without cortical calcifications: report of three families and a literature review.
J Alzheimers Dis 2017;56:37-46.
39. Fotiadis P, van Rooden S, van der Grond J, Schultz A, Martinez-Ramirez S, Auriel E, et al. Cortical atrophy in patients with cerebral amyloid angiopathy: a case-control study.
Lancet Neurol 2016;15:811-819.
40. van Etten ES, Gurol ME, van der Grond J, Haan J, Viswanathan A, Schwab KM, et al. Recurrent hemorrhage risk and mortality in hereditary and sporadic cerebral amyloid angiopathy.
Neurology 2016;87:1482-1487.
41. Martinez-Ramirez S, Romero JR, Shoamanesh A, McKee AC, Van Etten E, Pontes-Neto O, et al. Diagnostic value of lobar microbleeds in individuals without intracerebral hemorrhage.
Alzheimers Dement 2015;11:1480-1488.
42. Wollenweber FA, Baykara E, Zedde M, Gesierich B, Achmüller M, Jouvent E, et al. Cortical superficial siderosis in different types of cerebral small vessel disease.
Stroke 2017;48:1404-1407.
43. Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, et al. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy.
Neurology 2006;66:23-29.
44. Gurol ME, Viswanathan A, Gidicsin C, Hedden T, Martinez-Ramirez S, Dumas A, et al. Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study.
Ann Neurol 2013;73:529-536.
45. Charidimou A, Boulouis G, Haley K, Auriel E, van Etten ES, Fotiadis P, et al. White matter hyperintensity patterns in cerebral amyloid angiopathy and hypertensive arteriopathy.
Neurology 2016;86:505-511.
46. Smith EE, Gurol ME, Eng JA, Engel CR, Nguyen TN, Rosand J, et al. White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage.
Neurology 2004;63:1606-1612.
47. Chen YW, Gurol ME, Rosand J, Viswanathan A, Rakich SM, Groover TR, et al. Progression of white matter lesions and hemorrhages in cerebral amyloid angiopathy.
Neurology 2006;67:83-87.
48. Smith EE, Nandigam KR, Chen YW, Jeng J, Salat D, Halpin A, et al. MRI markers of small vessel disease in lobar and deep hemispheric intracerebral hemorrhage.
Stroke 2010;41:1933-1938.
49. Martinez-Ramirez S, Pontes-Neto OM, Dumas AP, Auriel E, Halpin A, Quimby M, et al. Topography of dilated perivascular spaces in subjects from a memory clinic cohort.
Neurology 2013;80:1551-1556.
50. Verbeek MM, Kremer BP, Rikkert MO, Van Domburg PH, Skehan ME, Greenberg SM. Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy.
Ann Neurol 2009;66:245-249.
51. Gurol ME, Becker JA, Fotiadis P, Riley G, Schwab K, Johnson KA, et al. Florbetapir-PET to diagnose cerebral amyloid angiopathy: a prospective study.
Neurology 2016;87:2043-2049.
52. Reyes S, Kurtz A, Hervé D, Tournier-Lasserve E, Chabriat H. Presymptomatic genetic testing in CADASIL.
J Neurol 2012;259:2131-2136.
53. Auer DP, Pütz B, Gössl C, Elbel G, Gasser T, Dichgans M. Differential lesion patterns in CADASIL and sporadic subcortical arteriosclerotic encephalopathy: MR imaging study with statistical parametric group comparison.
Radiology 2001;218:443-451.
54. van Etten ES, Auriel E, Haley KE, Ayres AM, Vashkevich A, Schwab KM, et al. Incidence of symptomatic hemorrhage in patients with lobar microbleeds.
Stroke 2014;45:2280-2285.
55. Thon JM, Gurol ME. Intracranial hemorrhage risk in the era of antithrombotic therapies for ischemic stroke.
Curr Treat Options Cardiovasc Med 2016;18:29.
56. Puy L, De Guio F, Godin O, Duering M, Dichgans M, Chabriat H, et al. Cerebral microbleeds and the risk of incident ischemic stroke in CADASIL (Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy).
Stroke 2017;48:2699-2703.
57. Lee JS, Ko K, Oh JH, Park JH, Lee HK, Floriolli D, et al. Cerebral microbleeds, hypertension, and intracerebral hemorrhage in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy.
Front Neurol 2017;8:203.
58. Rinnoci V, Nannucci S, Valenti R, Donnini I, Bianchi S, Pescini F, et al. Cerebral hemorrhages in CADASIL: report of four cases and a brief review.
J Neurol Sci 2013;330:45-51.
59. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence.
Stroke 2000;31:1062-1068.
60. SPS3 Investigators, Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.
N Engl J Med 2012;367:817-825.
61. Hanger HC, Wilkinson TJ, Fayez-Iskander N, Sainsbury R. The risk of recurrent stroke after intracerebral haemorrhage.
J Neurol Neurosurg Psychiatry 2007;78:836-840.
62. Haley KE, Greenberg SM, Gurol ME. Cerebral microbleeds and macrobleeds: should they influence our recommendations for antithrombotic therapies?
Curr Cardiol Rep 2013;15:425.
63. Gurol ME. Nonpharmacological management of atrial fibrillation in patients at high intracranial hemorrhage risk.
Stroke 2018;49:247-254.
64. Kwok CS, Shoamanesh A, Copley HC, Myint PK, Loke YK, Benavente OR. Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke: pooled analysis of randomized trials.
Stroke 2015;46:1014-1023.
65. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.
Lancet 2004;364:331-337.
66. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomized non-inferiority trial.
Lancet Neurol 2010;9:959-968.
67. Culebras A, Rotta-Escalante R, Vila J, Domínguez R, Abiusi G, Famulari A, et al. Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study.
Neurology 2004;62:1073-1080.
68. Uchiyama S, Shinohara Y, Katayama Y, Yamaguchi T, Handa S, Matsuoka K, et al. Benefit of cilostazol in patients with high risk of bleeding: subanalysis of cilostazol stroke prevention study 2.
Cerebrovasc Dis 2014;37:296-303.
69. Kim BJ, Lee EJ, Kwon SU, Park JH, Kim YJ, Hong KS, et al. Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial.
Lancet Neurol 2018;17:509-518.
70. Kim JS, Kwon SU, Uchiyama S. Cilostazol research in Asia: can it be applied to European and American patients?
Int J Stroke 2015;10 Suppl 1:1-9.
71. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.
N Engl J Med 2001;345:1444-1451.
72. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin.
Ann Neurol 1997;42:857-865.
73. Bath PM, Wardlaw JM. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions.
Int J Stroke 2015;10:469-478.
74. Wilson D, Al-Shahi Salman R, Klijn CJ, Lip GY, Werring DJ. Intracerebral haemorrhage, atrial fibrillation, and anticoagulation.
Lancet 2015;386:1736-1737.
75. Wilson D, Jäger HR, Werring DJ. Anticoagulation for atrial fibrillation in patients with cerebral microbleeds.
Curr Atheroscler Rep 2015;17:47.
76. Wang Z, Soo YO, Mok VC. Cerebral microbleeds: is antithrombotic therapy safe to administer?
Stroke 2014;45:2811-2817.
78. Biffi A, Kuramatsu JB, Leasure A, Kamel H, Kourkoulis C, Schwab K, et al. Oral anticoagulation and functional outcome after intracerebral hemorrhage.
Ann Neurol 2017;82:755-765.
79. Lammie GA. Hypertensive cerebral small vessel disease and stroke.
Brain Pathol 2002;12:358-370.
80. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging.
Lancet Neurol 2013;12:483-497.
81. Arima H, Anderson C, Omae T, Liu L, Tzourio C, Woodward M, et al. Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial.
J Hypertens 2010;28:395-400.
82. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al. Telmisartan to prevent recurrent stroke and cardiovascular events.
N Engl J Med 2008;359:1225-1237.
83. SPS3 Study Group, Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial.
Lancet 2013;382:507-515.
84. Biffi A, Anderson CD, Battey TW, Ayres AM, Greenberg SM, Viswanathan A, et al. Association between blood pressure control and risk of recurrent intracerebral hemorrhage.
JAMA 2015;314:904-912.
85. Li W, Jin C, Vaidya A, Wu Y, Rexrode K, Zheng X, et al. Blood pressure trajectories and the risk of intracerebral hemorrhage and cerebral infarction: a prospective study.
Hypertension 2017;70:508-514.
86. Huang Y, Cai X, Li Y, Su L, Mai W, Wang S, et al. Prehypertension and the risk of stroke: a meta-analysis.
Neurology 2014;82:1153-1161.
87. Ling Y, De Guio F, Duering M, Jouvent E, Hervé D, Godin O, et al. Predictors and clinical impact of incident lacunes in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.
Stroke 2017;48:283-289.
88. Pettersen JA, Keith J, Gao F, Spence JD, Black SE. CADASIL accelerated by acute hypotension: Arterial and venous contribution to leukoaraiosis.
Neurology 2017;88:1077-1080.
89. Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study.
Circulation 2005;112:666-673.
90. Najarian RM, Sullivan LM, Kannel WB, Wilson PW, D'Agostino RB, Wolf PA. Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study.
Arch Intern Med 2006;166:106-111.
91. Zhu S, McClure LA, Lau H, Romero JR, White CL, Babikian V, et al. Recurrent vascular events in lacunar stroke patients with metabolic syndrome and/or diabetes.
Neurology 2015;85:935-941.
92. Boulanger M, Poon MT, Wild SH, Al-Shahi Salman R. Association between diabetes mellitus and the occurrence and outcome of intracerebral hemorrhage.
Neurology 2016;87:870-878.
93. Palacio S, McClure LA, Benavente OR, Bazan C 3rd, Pergola P, Hart RG. Lacunar strokes in patients with diabetes mellitus: risk factors, infarct location, and prognosis: the secondary prevention of small subcortical strokes study.
Stroke 2014;45:2689-2694.
94. Stroke Prevetion by Aggressive Reduction in Cholestrol Levels (SPARCL) Investigators, Karam JG, Loney-Hutchinson L, Mc-Farlane SI. High-dose atorvastatin after stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.
J Cardiometab Syndr 2008;3:68-69.
95. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack.
N Engl J Med 2006;355:549-559.
96. Goldstein LB, Amarenco P, Szarek M, Callahan A 3rd, Hennerici M, Sillesen H, et al. Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study.
Neurology 2008;70(24 Pt 2):2364-2370.
97. Hassan A, Hunt BJ, O'Sullivan M, Bell R, D'Souza R, Jeffery S, et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction.
Brain 2004;127(Pt 1):212-219.
98. Maron BA, Loscalzo J. The treatment of hyperhomocysteinemia.
Annu Rev Med 2009;60:39-54.
99. Cavalieri M, Schmidt R, Chen C, Mok V, de Freitas GR, Song S, et al. B vitamins and magnetic resonance imaging-detected ischemic brain lesions in patients with recent transient ischemic attack or stroke: the VITAmins TO Prevent Stroke (VITATOPS) MRI-substudy.
Stroke 2012;43:3266-3270.
100. Ikram MA, Vernooij MW, Hofman A, Niessen WJ, van der Lugt A, Breteler MM. Kidney function is related to cerebral small vessel disease.
Stroke 2008;39:55-61.
101. Greenberg SM, Rosand J, Schneider AT, Creed Pettigrew L, Gandy SE, Rovner B, et al. A phase 2 study of tramiprosate for cerebral amyloid angiopathy.
Alzheimer Dis Assoc Disord 2006;20:269-274.